Add Yahoo as a preferred source to see more of our stories on Google. Former President Joe Biden was diagnosed with an "aggressive form" of prostate cancer that spread to the bone, a spokesperson said ...

Joe Biden has been diagnosed with an "aggressive form" of prostate cancer. Biden’s team shared a statement on Sunday that the former president was experiencing "increasing urinary symptoms" ahead of ...

Sextant biopsies have been routinely used by many urologists, and prostate cancer is often found in multiple biopsy sites from the same patient. Despite extensive studies on the predictive values of ...

In January 2021, a movement to redefine low-risk Gleason 6 lesions as noncancers or precancers made its debut in this blog under the headline: "Is This Really Cancer?" Urologic oncologist Scott ...

Please provide your email address to receive an email when new articles are posted on . Prolonged androgen deprivation therapy was associated with improved survival among men with Gleason grade groups ...

WASHINGTON -- Former President Joe Biden is battling an "aggressive" form of prostate cancer, his office announced on Sunday, adding his condition is characterized by a "Gleason score of 9." His ...

Association of baseline prostate atrophy with lower tumor volume in men with prostate cancer on repeat biopsy. Change in a 17-gene genomic prostate score over time in men with low- and ...

A team of researchers from Google Health, working with others from institutions across the U.S. and Canada has found that a Google AI system was able to outperform general pathologists when validating ...

Researchers at the UCLA Jonsson Comprehensive Cancer Center analyzed gene-expression patterns in the most aggressive prostate cancer grade group -- known as Gleason grade group 5 -- and found that ...

Add Yahoo as a preferred source to see more of our stories on Google. Over the weekend, President Joe Biden’s office announced that the former president has prostate cancer that has spread to his ...

Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter ...